Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patients were followed up. PN more commonly occurred af...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574429806362624 |
|---|---|
| author | S. S. Bessmeltsev E. V. Karyagina L. V Stelmashenko N. V. Stepanova E. R. Machulaiten G. N. Salogub I. A. Skorokhod N. V. Medvedeva E. I. Podoltseva L. M. Matyukhina A. S. Nizamutdinova K. M. Abdulkadyrov |
| author_facet | S. S. Bessmeltsev E. V. Karyagina L. V Stelmashenko N. V. Stepanova E. R. Machulaiten G. N. Salogub I. A. Skorokhod N. V. Medvedeva E. I. Podoltseva L. M. Matyukhina A. S. Nizamutdinova K. M. Abdulkadyrov |
| author_sort | S. S. Bessmeltsev |
| collection | DOAJ |
| description | The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patients were followed up. PN more commonly occurred after 3—5 cycles of bortezomib therapy. Grade > 2 PN was observed in 29% of the patients. The cumulative dose of bortezomib was 15.6 to 26 mg/m2. After 6—8 cycles the incidence of PN was also high. There was a correlation between the cumulative dose of bortezomib and the incidence of PN (R = 0.927; p < 0.0009). A correlation was also found between the incidence of PN and prior vincristine-containing treatment regimens (VAD scheme). Overall, PN was identified in 54% of the patients. Treatment of PN with gabapentin, pregabalin, vitamins B, and α-lipoic acid was effective. PN resolved to the baseline levels or the patients’ condition improved in 72% of the patients, the median time taken for resolution or improvement being 114 days. It is necessary to reduce the dose of bortezomib or to discontinue the drug temporarily in order to relieve the symptoms of neuropathy. |
| format | Article |
| id | doaj-art-d13b8f52d7bd41c4a2309ca155e24f5c |
| institution | Matheson Library |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-d13b8f52d7bd41c4a2309ca155e24f5c2025-08-04T13:57:52ZrusABV-pressОнкогематология1818-83462413-40232022-11-0103526210.17650/1818-8346-2008-0-3-52-62605Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)S. S. Bessmeltsev0E. V. Karyagina1L. V Stelmashenko2N. V. Stepanova3E. R. Machulaiten4G. N. Salogub5I. A. Skorokhod6N. V. Medvedeva7E. I. Podoltseva8L. M. Matyukhina9A. S. Nizamutdinova10K. M. Abdulkadyrov11Russian Research Institute of Hematology and TransfusiologyCity Hospital FifteenRussian Research Institute of Hematology and TransfusiologyRussian Research Institute of Hematology and TransfusiologyI.P. Pavlov Saint Petersburg State Medical UniversityI.P. Pavlov Saint Petersburg State Medical UniversityCity Hospital Thirty OneCity Hospital Thirty OneCity Hospital Thirty OneRoad Hospital, AOA “RZhD”Alexandrov HospitalRussian Research Institute of Hematology and TransfusiologyThe characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patients were followed up. PN more commonly occurred after 3—5 cycles of bortezomib therapy. Grade > 2 PN was observed in 29% of the patients. The cumulative dose of bortezomib was 15.6 to 26 mg/m2. After 6—8 cycles the incidence of PN was also high. There was a correlation between the cumulative dose of bortezomib and the incidence of PN (R = 0.927; p < 0.0009). A correlation was also found between the incidence of PN and prior vincristine-containing treatment regimens (VAD scheme). Overall, PN was identified in 54% of the patients. Treatment of PN with gabapentin, pregabalin, vitamins B, and α-lipoic acid was effective. PN resolved to the baseline levels or the patients’ condition improved in 72% of the patients, the median time taken for resolution or improvement being 114 days. It is necessary to reduce the dose of bortezomib or to discontinue the drug temporarily in order to relieve the symptoms of neuropathy.https://oncohematology.abvpress.ru/ongm/article/view/727bortezomibmultiple myelomaperipheral neuropathy |
| spellingShingle | S. S. Bessmeltsev E. V. Karyagina L. V Stelmashenko N. V. Stepanova E. R. Machulaiten G. N. Salogub I. A. Skorokhod N. V. Medvedeva E. I. Podoltseva L. M. Matyukhina A. S. Nizamutdinova K. M. Abdulkadyrov Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) Онкогематология bortezomib multiple myeloma peripheral neuropathy |
| title | Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) |
| title_full | Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) |
| title_fullStr | Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) |
| title_full_unstemmed | Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) |
| title_short | Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) |
| title_sort | incidence characteristics and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib velcade |
| topic | bortezomib multiple myeloma peripheral neuropathy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/727 |
| work_keys_str_mv | AT ssbessmeltsev incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT evkaryagina incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT lvstelmashenko incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT nvstepanova incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT ermachulaiten incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT gnsalogub incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT iaskorokhod incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT nvmedvedeva incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT eipodoltseva incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT lmmatyukhina incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT asnizamutdinova incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade AT kmabdulkadyrov incidencecharacteristicsandtreatmentsofperipheralneuropathyinmultiplemyelomapatientsreceivingbortezomibvelcade |